NDUFAB1 and alkaline phosphatase measurement: For HDL‐C (Table 1), targeting PPARG appeared to decrease the risk of AP (OR = 0.325, 95% CI 0.143–0.740, p = 0.007), AAP (OR = 0.045, 95% CI 0.006–0.363, p = 0.004), CP (OR = 0.295, 95% CI 0.100–0.871, p = 0.027), and ACP (OR = 0.187, 95% CI 0.041–0.852, p = 0.030), while targeting APOB and APOC3 appeared to be associated with reduced risk of CP (APOB: OR = 0.459, 95% CI 0.262–0.805, p = 0.007; APOC3: OR = 0.580, 95% CI 0.364–0.924, p = 0.022), and ACP (APOB: OR = 0.417, 95% CI 0.190–0.916, p = 0.029; APOC3: OR = 0.412, 95% CI 0.214–0.972, p = 0.008).